The central cholinergic system profile of olanzapine compared with placebo in Alzheimer's disease

The objective of this analysis was to compare the treatment‐emergent central anticholinergic‐like adverse events experienced during treatment with olanzapine versus placebo in patients with psychosis and/or agitation due to Alzheimer's disease (AD). In addition, changes in cognition were assessed in a subgroup of patients with mild to moderate cognitive impairment.

[1]  J. Cummings,et al.  The use of the neuropsychiatric inventory in nursing home residents. Characterization and measurement. , 2000, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[2]  R. Tamura,et al.  Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. , 2000, Archives of general psychiatry.

[3]  F. Bymaster,et al.  The Comparative Peripheral Anticholinergic-Like Adverse Event Profiles of Olanzapine and Risperidone. , 2000, Primary care companion to the Journal of clinical psychiatry.

[4]  Douglas W. Jones,et al.  In Vivo Olanzapine Occupancy of Muscarinic Acetylcholine Receptors in Patients with Schizophrenia , 2000, Neuropsychopharmacology.

[5]  B. Pollock,et al.  Anticholinergic differences among patients receiving standard clinical doses of olanzapine or clozapine. , 2000, Journal of clinical psychopharmacology.

[6]  T. Branchek,et al.  5-ht6 receptors as emerging targets for drug discovery. , 2000, Annual review of pharmacology and toxicology.

[7]  F. Bymaster,et al.  Decreased binding affinity of olanzapine and clozapine for human muscarinic receptors in intact clonal cells in physiological medium. , 2000, European journal of pharmacology.

[8]  A Labelle,et al.  Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. , 2000, Archives of general psychiatry.

[9]  S. Tsai,et al.  Association analysis of the 5-HT6 receptor polymorphism C267T in Alzheimer's disease , 1999, Neuroscience Letters.

[10]  F. Bymaster,et al.  Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and α 1-adrenergic receptors in vitro , 1999, Schizophrenia Research.

[11]  D. Kiely,et al.  The association of serum anticholinergic activity with delirium in elderly medical patients. , 1998, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[12]  A. Sleight,et al.  Characterization of Ro 04‐6790 and Ro 63‐0563: potent and selective antagonists at human and rat 5‐HT6 receptors , 1998, British journal of pharmacology.

[13]  J. Arnt,et al.  Do Novel Antipsychotics Have Similar Pharmacological Characteristics? A Review of the Evidence , 1998, Neuropsychopharmacology.

[14]  Philip Seeman,et al.  Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine , 1996, Neuropsychopharmacology.

[15]  Charles M Beasley,et al.  Olanzapine versus Placebo and Haloperidol , 1996, Neuropsychopharmacology.

[16]  D. Mash,et al.  Loss of high‐affinity agonist binding to M1 muscarinic receptors in Alzheimer's disease: Implications for the failure of cholinergic replacement therapies , 1991, Annals of neurology.

[17]  Z. J. Lipowski.  Delirium: Acute Confusional States , 1990 .

[18]  E. Perry,et al.  Guanine nucleotide modulation of muscarinic cholinergic receptor binding in postmortem human brain — A preliminary study in Alzheimer's disease , 1987, Neuroscience Letters.

[19]  D. Keegan,et al.  Mental dysfunction and the blockade of muscarinic receptors in the brains of the normal elderly , 1985, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[20]  F. Bymaster,et al.  The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors , 1999, Psychopharmacology.

[21]  D. T. Dudley,et al.  Chapter 54: Subtype selective muscarinic agonists: potential therapeutic agents for Alzheimer's disease , 1993 .

[22]  G. Tollefson,et al.  The relationship of serum anticholinergic activity to mental status performance in an elderly nursing home population. , 1991, The Journal of neuropsychiatry and clinical neurosciences.